Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Mixed Response To Indiplon Is Pfizer/Neurocrine’s Rude Awakening

This article was originally published in The Pink Sheet Daily

Executive Summary

Neurocrine will meet with FDA within 10 days to discuss the “approvable” and “not approvable” letters for the insomnia product.

You may also be interested in...



Neurocrine’s Bad Dream Continues: Indiplon FDA Approval Requires Three More Studies

FDA “approvable” letter for the insomnia agent is particularly stinging because Neurocrine was set to announce a new commercialization agreement with a leading pharma company.

Neurocrine’s Bad Dream Continues: Indiplon FDA Approval Requires Three More Studies

FDA “approvable” letter for the insomnia agent is particularly stinging because Neurocrine was set to announce a new commercialization agreement with a leading pharma company.

Neurocrine Partners With Dainippon To Market Indiplon In Japan

Dainippon Sumitomo will market Neurocrine Biosciences' insomnia agent indiplon in Japan under an exclusive liensing agreement announced Nov. 1

Related Content

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel